About Us
A progressive pioneer in oral, transdermal drug delivery systems.
Our pipeline of medicines strives to bridge the gap that patients face in current treatments.
From concept to commercial, we provide dedicated solutions to partner pharma's ambition. With products and partners on three continents, we advance DDS forefront to promote partner value and raise patient outcomes.
From concept to commercial, we provide dedicated solutions to partner pharma's ambition. With products and partners on three continents, we advance DDS forefront to promote partner value and raise patient outcomes.
TECHNOLOGY PLATFORM
-
Transdermal Delivery
- Daily to Weekly Release
- Stable Plasma Level
- No First-Pass Metabolism
- Convenient and Consistant
-
Transmucosal Delivery
- No Water Needed
- No Choking Risk
- Ideal Take-Away Medicine
- Great Lifecycle Management
news&event
-
04.21 2021
公告本公司TAH9922小兒過動症口服液 (Atomoxetine oral solution)產品專利已通過審查獲得美國專利許可。
本公司所研發之TAH9901小兒過動症貼片(Methylphenidate Transdermal Patch)產品 專利，專利名稱「Transdermal Delivery System Containing Methylphenidate Or Its Salts and Methods Thereof」，已通過美國專利及商標局審查獲得美國專利許可
